Laster
x
Denne nettsiden bruker viktige informasjonskapsler. Med ditt samtykke plasserer vi Google Analytics informasjonskapsler for statistikk.

Cookie Policy for Slzii.com

Dette er retningslinjene for informasjonskapsler for Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

Søk (Nyheter)

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent carbon footprint data for clients INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting. The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices. Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparability of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements. "Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients," said John Rim, President and CEO of Samsung Biologics. "This represents the company's continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners." Samsung Biologics' sustainability efforts have also been recognized through its recent EcoVadis assessment, where the company received a Platinum rating, placing it among the top one percent of companies evaluated globally for sustainability management. For more information on Samsung Biologics' sustainability efforts, please visit the company's website. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenSTM framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, visit https://samsungbiologics.com/. Media Contact Claire Kim, Senior Director cair.kim@samsung.com Becky Lee, Director brite.lee@samsung.com
2026-02-06 13:00:00

0.047119140625


Nyheter
Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

Nyheter
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent carbon footprint data for clients INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting. The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices. Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparability of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements. Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients, said John Rim, President and CEO of Samsung Biologics. This represents the company's continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners. Samsung Biologics' sustainability efforts have also been recognized through its recent EcoVadis assessment, where the company received a Platinum rating, placing it among the top one percent of companies evaluated globally for sustainability management. For more information on Samsung Biologics' sustainability efforts, please visit the company's website. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenSTM framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, visit https://samsungbiologics.com/. Media Contact Claire Kim, Senior Director cair.kim@samsung.com Becky Lee, Director brite.lee@samsung.com
Nyheter